This SBE supplement covers the development of continuous processing techniques in upstream and downstream biopharmaceutical processes. It also details factors that are impeding end-to-end implementation of continuous biopharmaceutical manufacturing processes, and points out that despite some misconceptions, regulators such as the U.S. Food and Drug Administration (FDA), encourage, rather than prevent, continuous processing. Other topics in this issue include cyclic ditillation and France's chemical industry.
